(NewsDirect)
Algernon Pharmaceuticals CEO Christopher Moreau said the companyhas announced that its subsidiary Algernon NeuroScience has dosed thefirst subject in the Phase 1 DMT clinical stroke study. Moreau toldProactive this dosing was in the Netherlands where the study is beingconducted at the Centre for Human Drug Research in Leiden. The firstpart of the study will use a single-escalating dose design aimed atidentifying a safe and tolerable dose that will not producepsychedelic effects.
ProactiveCanada Financial News
ContactDetails
Proactive Canada
ProactiveCanada
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.